TREATMENT TRIAL AND LONG-TERM FOLLOW-UP EVALUATION AMONG COMORBID YOUTH WITH MAJOR DEPRESSION AND A CANNABIS USE DISORDER

Overview

Journal Int J Med Biol Front

Specialty Biology

Date 2014 Oct 21

PMID 25328373

Citations 3

Authors

Jack R Cornelius

Ihsan M Salloum

Robert Ferrell

Antoine B Douaihy

Jeanie Hayes

Levent Kirisci

Michelle Horner

Dennis C Daley

Affiliations

Soon will be listed here.

Abstract

Objective: This study compared the acute phase (12-week) and the long-term (1 year) efficacy of fluoxetine versus placebo for the treatment of the depressive symptoms and the cannabis use of youth with comorbid major depressive disorder (MDD) and an cannabis use disorder (CUD)(cannabis dependence or cannabis abuse). We hypothesized that fluoxetine would demonstrate efficacy in the acute phase trial and at the 1-year follow-up evaluation. Data is also provided regarding the prevalence of risky sexual behaviors in our study sample.

Methods: We recently completed the first double-blind placebo-controlled study of fluoxetine in adolescents and young adults with comorbid MDD/CUD. A total of 70 persons participated in the acute phase trial, and 68 of those persons (97%) also participated in the 1-year follow-up evaluation. Results of the acute phase study have already been presented (Cornelius, Bukstein, et al., 2010), but the results of the 1 year follow-up assessment have not been published previously. All participants in both treatment groups also received manual-based cognitive behavioral therapy (CBT) and motivation enhancement therapy (MET) during the 12-week course of the study. The 1-year follow-up evaluation was conducted to assess whether the clinical improvements noted during the acute phase trial persisted long term.

Results: During the acute phase trial, subjects in both the fluoxetine group and the placebo group showed significant within-group improvement in depressive symptoms and in cannabis-related symptoms. However, no significant difference was noted between the floxetine group and the placebo group on any treatment outcome variable during the acute phase trial. End of study levels of depressive symptoms were low in both the fluoxetine group and the placebo group. Most of the clinical improvements in depressive symptoms and for cannabis-related symptoms persisted at the 1-year follow-up evaluation.

Conclusions: Fluoxetine did not demonstrate greater efficacy than placebo for treating either the depressive symptoms or the cannabis-related symptoms of our study sample during the acute phase study or at the 1-year follow-up assessment. The lack of a significant treatment effect for fluoxetine may at least in part reflect efficacy of the CBT/MET psychotherapy. A persistence of the efficacy of the acute phase treatment was noted at the 1-year follow-up evaluation, suggesting long-term effectiveness for the CBT/MET psychotherapy.

Citing Articles

A systematic review of evidence on integrated management of psychiatric disorders in youth who use cannabis.

Vidal C, Simon K, Brooks C, White J, Hinckley J Drug Alcohol Depend Rep. 2024; 10:100216.

PMID: 38288007 PMC: 10823056. DOI: 10.1016/j.dadr.2023.100216.

Down and High: Reflections Regarding Depression and Cannabis.

Langlois C, Potvin S, Khullar A, Tourjman S Front Psychiatry. 2021; 12:625158.

PMID: 34054594 PMC: 8160288. DOI: 10.3389/fpsyt.2021.625158.

Pharmacotherapies for cannabis dependence.

Nielsen S, Gowing L, Sabioni P, Le Foll B Cochrane Database Syst Rev. 2019; 1:CD008940.

PMID: 30687936 PMC: 6360924. DOI: 10.1002/14651858.CD008940.pub3.

References

Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P . Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997; 36(7):980-8. DOI: 10.1097/00004583-199707000-00021. View

March J, Silva S, Compton S, Anthony G, DeVeaugh-Geiss J, Califf R . The Child and Adolescent Psychiatry Trials Network (CAPTN). J Am Acad Child Adolesc Psychiatry. 2004; 43(5):515-8. DOI: 10.1097/00004583-200405000-00004. View

Emslie G, Rush A, Weinberg W, Kowatch R, Hughes C, Carmody T . A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997; 54(11):1031-7. DOI: 10.1001/archpsyc.1997.01830230069010. View

Chen C, Wagner F, Anthony J . Marijuana use and the risk of Major Depressive Episode. Epidemiological evidence from the United States National Comorbidity Survey. Soc Psychiatry Psychiatr Epidemiol. 2002; 37(5):199-206. DOI: 10.1007/s00127-002-0541-z. View

. Biological factors in prepubertal major depression. Pediatr Ann. 1986; 15(12):867, 870-2, 873-4. DOI: 10.3928/0090-4481-19861201-09. View

Stinson F, Ruan W, Pickering R, Grant B . Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med. 2006; 36(10):1447-60. DOI: 10.1017/S0033291706008361. View

Festinger D, Marlowe D, Dugosh K, Croft J, Arabia P . Higher magnitude cash payments improve research follow-up rates without increasing drug use or perceived coercion. Drug Alcohol Depend. 2008; 96(1-2):128-35. PMC: 2475801. DOI: 10.1016/j.drugalcdep.2008.02.007. View

Cornelius J, Bukstein O, Douaihy A, Clark D, Chung T, Daley D . Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010; 112(1-2):39-45. PMC: 2946416. DOI: 10.1016/j.drugalcdep.2010.05.010. View

Birmaher B, Brent D, Kolko D, Baugher M, Bridge J, Holder D . Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry. 2000; 57(1):29-36. DOI: 10.1001/archpsyc.57.1.29. View

10.

Martin C, Pollock N, Bukstein O, Lynch K . Inter-rater reliability of the SCID alcohol and substance use disorders section among adolescents. Drug Alcohol Depend. 2000; 59(2):173-6. DOI: 10.1016/s0376-8716(99)00119-2. View

11.

Jain U, Birmaher B, Garcia M, Al-Shabbout M, Ryan N . Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects. J Child Adolesc Psychopharmacol. 2009; 2(4):259-65. DOI: 10.1089/cap.1992.2.259. View

12.

Bailey S, Camlin C, Ennett S . Substance use and risky sexual behavior among homeless and runaway youth. J Adolesc Health. 1998; 23(6):378-88. PMC: 2882621. DOI: 10.1016/s1054-139x(98)00033-0. View

13.

Fournier J, DeRubeis R, Hollon S, Dimidjian S, Amsterdam J, Shelton R . Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010; 303(1):47-53. PMC: 3712503. DOI: 10.1001/jama.2009.1943. View

14.

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

15.

Nordstrom B, Levin F . Treatment of cannabis use disorders: a review of the literature. Am J Addict. 2007; 16(5):331-42. DOI: 10.1080/10550490701525665. View

16.

Nunes E, Levin F . Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004; 291(15):1887-96. DOI: 10.1001/jama.291.15.1887. View

17.

Brent D, Holder D, Kolko D, Birmaher B, Baugher M, Roth C . A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry. 1997; 54(9):877-85. DOI: 10.1001/archpsyc.1997.01830210125017. View

18.

Bailey S, Gao W, Clark D . Diary study of substance use and unsafe sex among adolescents with substance use disorders. J Adolesc Health. 2006; 38(3):297.e13-20. DOI: 10.1016/j.jadohealth.2004.12.001. View

19.

Stephens R, Roffman R, Curtin L . Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol. 2000; 68(5):898-908. View

20.

Klein R, Mannuzza S, Koplewicz H, Tancer N, Shah M, Liang V . Adolescent depression: controlled desipramine treatment and atypical features. Depress Anxiety. 1998; 7(1):15-31. DOI: 10.1002/(sici)1520-6394(1998)7:1<15::aid-da3>3.0.co;2-4. View